A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Clinical trial NCT05745740 · UNKNOWN

Trial details

NCT number: NCT05745740
Sponsor: RemeGen Co., Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2024-04-01
Primary completion: 2025-12-01
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.